论文部分内容阅读
目的 :观察兰他隆 (lentaron)治疗绝经后晚期和复发性乳腺癌患者的疗效和副作用。方法 :1998年 11月～ 1999年 9月对 17例绝经后晚期和复发性乳腺癌患者给予兰他隆 2 50mg肌肉注射 ,每2周 1次 ,至少 2个月。结果 :无完全缓解者 ,部分缓解率 2 9 4 1% (5/ 17) ,稳定 6 4 71% (11/ 17) ,进展5 88% (1/ 17)。治疗中出现轻度副作用 7例 ,无严重不良反应。结论 :兰他隆对于绝经后乳腺癌患者疗效好、不良反应发生率低 ,是复发性乳腺癌以及不能耐受手术、化疗的原发性乳腺癌的首选药。
OBJECTIVE: To observe the efficacy and side effects of lentaron in the treatment of patients with advanced and recurrent breast cancer after menopause. METHODS: From November 1998 to September 1999, 17 patients with late-stage and recurrent breast cancer were given intramuscular injection of 25 mg of randaton once every two weeks for at least 2 months. Results: In those without complete remission, the partial response rate was 2941% (5/17), stable to 6.411% (11/17), and the progress was 58.8% (1/17). There were 7 mild side effects in the treatment without serious adverse reactions. CONCLUSIONS: Lantotralin is effective in treating postmenopausal women with breast cancer and has a low incidence of adverse reactions. It is the first choice for recurrent breast cancer and primary breast cancer that can not tolerate surgery and chemotherapy.